Abstract
The blood-brain barrier (BBB) poses a unique challenge for drug delivery to the central nervous system (CNS). The BBB consists of a continuous layer of specialized endothelial cells linked together by tight junctions, pericytes, nonfenestrated basal lamina, and astrocytic foot processes. This complex barrier controls and limits the systemic delivery of therapeutics to the CNS. Several innovative strategies have been explored to enhance the transport of therapeutics across the BBB, each with individual advantages and disadvantages. Ongoing advances in delivery approaches that overcome the BBB are enabling more effective therapies for CNS diseases. In this review, we discuss: (1) the physiological properties of the BBB, (2) conventional strategies to enhance paracellular and transcellular transport through the BBB, (3) emerging concepts to overcome the BBB, and (4) alternative CNS drug delivery strategies that bypass the BBB entirely. Based on these exciting advances, we anticipate that in the near future, drug delivery research efforts will lead to more effective therapeutic interventions for diseases of the CNS.
Keywords: Central Nervous System (CNS), Blood-Brain Barrier (BBB), nanotechnology, ultrasound, immunotherapy.
Current Pharmaceutical Design
Title:Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
Volume: 22 Issue: 9
Author(s): David S. Hersh, Aniket S. Wadajkar, Nathan B. Roberts, Jimena G. Perez, Nina P. Connolly, Victor Frenkel, Jeffrey A. Winkles, Graeme F. Woodworth and Anthony J. Kim
Affiliation:
Keywords: Central Nervous System (CNS), Blood-Brain Barrier (BBB), nanotechnology, ultrasound, immunotherapy.
Abstract: The blood-brain barrier (BBB) poses a unique challenge for drug delivery to the central nervous system (CNS). The BBB consists of a continuous layer of specialized endothelial cells linked together by tight junctions, pericytes, nonfenestrated basal lamina, and astrocytic foot processes. This complex barrier controls and limits the systemic delivery of therapeutics to the CNS. Several innovative strategies have been explored to enhance the transport of therapeutics across the BBB, each with individual advantages and disadvantages. Ongoing advances in delivery approaches that overcome the BBB are enabling more effective therapies for CNS diseases. In this review, we discuss: (1) the physiological properties of the BBB, (2) conventional strategies to enhance paracellular and transcellular transport through the BBB, (3) emerging concepts to overcome the BBB, and (4) alternative CNS drug delivery strategies that bypass the BBB entirely. Based on these exciting advances, we anticipate that in the near future, drug delivery research efforts will lead to more effective therapeutic interventions for diseases of the CNS.
Export Options
About this article
Cite this article as:
Hersh S. David, Wadajkar S. Aniket, Roberts B. Nathan, Perez G. Jimena, Connolly P. Nina, Frenkel Victor, Winkles A. Jeffrey, Woodworth F. Graeme and Kim J. Anthony, Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier, Current Pharmaceutical Design 2016; 22 (9) . https://dx.doi.org/10.2174/1381612822666151221150733
DOI https://dx.doi.org/10.2174/1381612822666151221150733 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Patents on Genetic Programming
Recent Patents on Computer Science The Development of Future Research Strategies from Reviewing Antiemetic Trials for Chemotherapy Induced Emesis
Reviews on Recent Clinical Trials MTA1: A Vital Modulator in Prostate Cancer
Current Protein & Peptide Science Upregulation of DLX2 Confers a Poor Prognosis in Glioblastoma Patients by Inducing a Proliferative Phenotype
Current Molecular Medicine Safety of Multi-Targeted Kinase Inhibitors as Monotherapy Treatment of Cancer: A Systematic Review of the Literature
Current Drug Safety The Molecular Pathology of Eye Tumors: A 2019 Update Main Interests for Routine Clinical Practice
Current Molecular Medicine Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Current Drug Targets De Novo DNMTs and DNA Methylation: Novel Insights into Disease Pathogenesis and Therapy from Epigenomics
Current Pharmaceutical Design Targeting Protein-Protein and Protein-Nucleic Acid Interactions for Anti-HIV Therapy
Current Pharmaceutical Design State-of-the-Art Magnetic Resonance Spectroscopy in Oncologic Imaging
Current Molecular Imaging (Discontinued) Ribozymes in the Age of Molecular Therapeutics
Current Molecular Medicine Improving Peptide Applications Using Nanotechnology
Current Topics in Medicinal Chemistry Cancer Nanotechnology - Prospects for Cancer Diagnostics and Therapy
Current Cancer Therapy Reviews Circumventing Immune Tolerance Through Epigenetic Modification
Current Pharmaceutical Design Advances in Gene Therapy for Bladder Cancer
Current Gene Therapy To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors
Current Topics in Medicinal Chemistry Biosynthetic Pathways to Glycosidase Inhibitors
Current Chemical Biology Association of Posture Instability with Dopamine Drop of Nigrostriatal System and Hypometabolism of Cerebral Cortex in Parkinson’s Disease
Current Neurovascular Research Akt Pathway Inhibitors
Current Topics in Medicinal Chemistry Recent Development in Nano-Sized Dosage Forms of Plant Alkaloid Camptothecin-Derived Drugs
Recent Patents on Anti-Cancer Drug Discovery